You are here: Home » Companies » News
Business Standard

Orchid Pharma gets favourable US FDA report for manufacturing unit

Along with US FDA, it has received approvals from various regulatory agencies like UK MHRA, MCC (South Africa) and Danish Medicines Agency

BS Reporter  |  Chennai 

Global Pharmaceutical M&A deals

Orchid Pharma today announced that it had received favourable inspection report from US Food and Drug Administration (FDA) for its manufacturing facility near Chennai.

The company said it received the Establishment Inspection Report (EIR) from US FDA based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, in Kancheepuram district. The facility was inspected by the authorities in May 2015.

The facility, for manufacturing generic oral formulations, has been inspected and approved by various regulatory agencies including the US FDA, UK MHRA, MCC (South Africa) and Danish Medicines Agency, based on specific filings in the past, the company said.

Following the announcement, the share price of the company went up over 14% from Rs 58 a share to Rs 66.4 a share on Thursday afternoon. It later closed at Rs 64.90 apiece, up 9.91%.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, December 31 2015. 17:32 IST